HR+/HER2- Breast Cancer Market Set To Triple

The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.

The hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer market was worth $3.4bn across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) in 2015, according to new Datamonitor Healthcare estimates. This figure is forecast to steadily increase, reaching a peak of $10.7bn in 2022 before falling back down to $9.6bn in 2024.

Despite the drop off in the last two years of the forecast, the market is projected to increase at a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category